Show simple item record

dc.contributor.authorIsasti Iribar, Amaia
dc.contributor.authorBorrega Román, Leire
dc.contributor.authorSaumell Esnaola, Miquel
dc.contributor.authorGonzález Burguera, Imanol
dc.contributor.authorBarrondo Lacarra, Sergio ORCID
dc.contributor.authorSallés Alvira, Joan
dc.contributor.authorGarcía del Caño, Gontzal
dc.contributor.authorLópez de Jesús, Maider ORCID
dc.date.accessioned2020-11-12T18:31:22Z
dc.date.available2020-11-12T18:31:22Z
dc.date.issued2020
dc.identifier.citationEkaia 38 : 27-40 (2020)
dc.identifier.issn0214-9001
dc.identifier.urihttp://hdl.handle.net/10810/47921
dc.description.abstractCurrently, Cerebrovascular accident (CVA) also known as stroke, is the third leading cause of disability and death worldwide. CVA is a sudden alteration of cerebral circulation, which results in neural cell death and consequently a temporary or permanent loss in certain neuronal functions. Therefore, in addition to working on prevention, in clinical practice is essential to have effective treatments aimed at avoiding neuronal dead. Unfortunately, the efficacy of the currently used therapeutic strategies is limited and, in most cases, patients suffering from stroke do not recover an adequate quality of life. This article presents cell therapy as a future alternative of interest in the treatment of chronic patients of CVA. This new therapy aims to replace the lost neuronal cells that are the main cause of disability in patients. Specifically, the review article presents recent progress on the use of teratocarcinoma-derived Ntera2/D1 neuronlike cells (NT2N cells), as graft source for cell transplantation in stroke, discussing the safety and efficacy demonstrated by preclinical and clinical trials made to date.; Gaur egun, istripu zerebrobaskularra (IZB) mundu osoan bigarren heriotza-kausa eta ezgaitasunen hirugarren eragilea da. IZB, garuneko zirkulazioaren bat-bateko asaldura da, non, neuronen galera baten ondorioz, aldi baterako edo betirako garunaren eskualde jakin baten funtzioa eraldatzen den. Hortaz, praktika klinikoan, prebentzioan lan egiteaz gain, ezinbestekoa da funtzio neurologikoen galeraren oinarrian dagoen neuronen heriotzaren kontra zuzendutako tratamendu eraginkorrak izatea. Tamalez, gaur egun erabiltzen diren estrategia terapeutikoen eraginkortasuna mugatua da, eta, kasu gehienetan, IZB izandako pazienteek ez dute bizi-kalitate egokia berreskuratzen. Artikulu honetan, gaixoen ezgaitasunaren arrazoia den neuronen galerari aurre egiteko zelula hauen ordezkapena itu duen terapia zelularra aurkezten da. Zehazki, Ntera2/D1 edo NT2 deituriko zelula-lerrotik eratorritako zelula neuronalen (NT2N) transplantean sakontzen dugu, IZB izandako gaixoetan estrategia berri bezala eskainiko lituzkeen abantailak eta gaur egun arte egindako entsegu pre-klinikoetan zein klinikoetan frogatutako segurtasuna eta eraginkortasuna aztertuz.
dc.language.isoeus
dc.publisherServicio Editorial de la Universidad del País Vasco/Euskal Herriko Unibertsitatearen Argitalpen Zerbitzua
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.titleTeratokartzinometatik eratorritako zelula-lerro neuronalen (NT2N) trasplantea: istripu zerebrobaskularra izandako gaixo kronikoentzako estrategia terapeutiko berria
dc.typeinfo:eu-repo/semantics/article
dc.rights.holder© 2020 UPV/EHU Attribution-NonCommercial-ShareAlike 4.0 International
dc.identifier.doi10.1387/ekaia.21296


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2020 UPV/EHU Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as © 2020 UPV/EHU Attribution-NonCommercial-ShareAlike 4.0 International